However, with the crystal structure of SmgGDS now solved (Shimizu et al., 2018), developing small chemical inhibitors to disrupt interactions between SmgGDS and specific GTPase partners is a promising strategy to diminish the activity of oncogenic small GTPases in cancer, and potentially to regulate the activities of small GTPases that interact with SmgGDS in other disorders. Here, RAP1GDS1 is linked to cancer.